Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

NCT03884439 COMPLETED Results posted

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.

Details

Lead sponsor	Pfizer
Status	COMPLETED
Enrolment	428
Start date	Mon Mar 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Feb 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Crohn's Disease
• Ulcerative Colitis

Interventions

• Infliximab [infliximab biosimilar 3]

Countries

Japan